Cognition Therapeutics, Inc. (CGTX)
CGTX Stock Price Chart
Explore Cognition Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CGTX price movements and trends.
CGTX Company Profile
Discover essential business fundamentals and corporate details for Cognition Therapeutics, Inc. (CGTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Oct 2021
Employees
25.00
Website
https://www.cogrx.comCEO
Lisa Ricciardi
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
CGTX Financial Timeline
Browse a chronological timeline of Cognition Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.07.
Earnings released on 7 Aug 2025
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%.
Earnings released on 7 May 2025
EPS came in at -$0.14 falling short of the estimated -$0.12 by -16.67%.
Earnings released on 20 Mar 2025
EPS came in at -$0.17 falling short of the estimated -$0.16 by -6.25%.
Earnings released on 13 Nov 2024
EPS came in at -$0.25 falling short of the estimated -$0.24 by -4.17%.
Earnings released on 8 Aug 2024
EPS came in at -$0.18 surpassing the estimated -$0.22 by +18.18%.
Earnings released on 7 May 2024
EPS came in at -$0.27 falling short of the estimated -$0.23 by -17.39%.
Earnings released on 26 Mar 2024
EPS came in at -$0.27 surpassing the estimated -$0.38 by +28.95%, while revenue for the quarter reached $372.00K .
Earnings released on 2 Nov 2023
EPS came in at -$0.22 surpassing the estimated -$0.31 by +29.03%.
Earnings released on 8 Aug 2023
EPS came in at -$0.16 surpassing the estimated -$0.25 by +36.00%.
Earnings released on 4 May 2023
EPS came in at -$0.21 falling short of the estimated -$0.17 by -23.53%.
Earnings released on 23 Mar 2023
EPS came in at -$0.20 surpassing the estimated -$0.49 by +59.18%.
Earnings released on 14 Nov 2022
EPS came in at -$0.29 surpassing the estimated -$0.55 by +47.27%.
Earnings released on 9 Aug 2022
EPS came in at -$0.25 surpassing the estimated -$0.31 by +19.35%.
Earnings released on 11 May 2022
EPS came in at -$0.17 surpassing the estimated -$0.27 by +37.04%.
Earnings released on 30 Mar 2022
EPS came in at -$11.74 falling short of the estimated -$0.26 by -4.42K%.
Earnings released on 17 Nov 2021
EPS came in at -$8.12 falling short of the estimated -$0.57 by -1.32K%.
Earnings released on 8 Oct 2021
EPS came in at -$0.07 .
Earnings released on 31 Mar 2021
EPS came in at $0.01 .
Earnings released on 31 Dec 2020
EPS came in at -$0.09 .
Earnings released on 30 Sept 2020
EPS came in at -$0.08 .
CGTX Stock Performance
Access detailed CGTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.